Dec. 6 (Bloomberg) -- Pfizer Inc. must pay $72.6 million in damages to three women who contended they developed breast cancer after taking the company’s menopause drugs, a Philadelphia jury decided.
Jurors in state court deliberated over two days before finding today that hormone-replacement drugs made by Pfizer’s Wyeth and Pharmacia Upjohn units were responsible for cancer in Susan Elfont, Bernadette Kalenkoski and Judy Mulderig. The panel awarded Elfont $20 million; Kalenkoski, $27.85 million; and Mulderig, $24.75 million.
“We are obviously disappointed with the verdict in this case, Chris Loder, a Pfizer spokesman, said in a written statement. “Once the verdict is finalized, the company will weigh its legal options to determine how it will continue with the case.”
More than 6 million women took Prempro and related menopause drugs to treat symptoms such as hot flashes and mood swings before a 2002 study highlighted their links to cancer. Wyeth’s sales of the medicines, which are still on the market, topped $2 billion before the release of the Women’s Health Initiative, a National Institutes of Health-sponsored study.
Tuesday, December 06, 2011
Pfizer Loses $72.6 Million Verdict in Breast Cancer Suit - Businessweek